Pembrolizumab Combined With Cisplatin-based Chemotherapy as First-line Systemic Therapy in Advanced Penile Cancer
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This is a phase II clinical trial evaluating activity, safety and patients reported outcomes
of first-line pembrolizumab plus cisplatin (or carboplatin) plus 5-FU for patients with
advanced penile squamous cell carcinoma.
The primary endpoint is overall responsa rate according to RECIST v1.1 at week 24.